Combination of taxol and Bcl-2 siRNA induces apoptosis in human glioblastoma cells and inhibits invasion, angiogenesis and tumour growth

Journal of Cellular and Molecular Medicine

Volumn 13, Issue 10, 2009, Pages 4205-4218

  George, Joseph ^a   Banik, Naren L ^b   Ray, Swapan K ^a  

^a UNIVERSITY OF SOUTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

Angiogenesis; Apoptosis; Bcl 2 siRNA; Cell invasion; Glioblastoma; Taxol

Indexed keywords

CASPASE 3; CASPASE 9; MESSENGER RNA; PACLITAXEL; PROTEIN BCL 2; SMALL INTERFERING RNA;

ANIMAL; APOPTOSIS; ARTICLE; CANCER INVASION; CELL PROLIFERATION; CELL SURVIVAL; DOWN REGULATION; DRUG EFFECT; DRUG SCREENING; ENZYMOLOGY; FLOW CYTOMETRY; GENE EXPRESSION REGULATION; GENETICS; GLIOBLASTOMA; HUMAN; METABOLISM; MOUSE; MULTIMODALITY CANCER THERAPY; NEOVASCULARIZATION (PATHOLOGY); NICK END LABELING; PATHOLOGY; SUBCUTANEOUS TISSUE; TUMOR CELL LINE; DRUG EFFECTS; NEOVASCULARIZATION, PATHOLOGIC; TUMOR INVASION;

ANIMALS; APOPTOSIS; CASPASE 3; CASPASE 9; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; COMBINED MODALITY THERAPY; DOWN-REGULATION; FLOW CYTOMETRY; GENE EXPRESSION REGULATION, NEOPLASTIC; GLIOBLASTOMA; HUMANS; IN SITU NICK-END LABELING; MICE; NEOPLASM INVASIVENESS; NEOVASCULARIZATION, PATHOLOGIC; PACLITAXEL; PROTO-ONCOGENE PROTEINS C-BCL-2; RNA, MESSENGER; RNA, SMALL INTERFERING; SUBCUTANEOUS TISSUE; XENOGRAFT MODEL ANTITUMOR ASSAYS;

MUS MUSCULUS;

EID: 73149094257     PISSN: 15821838     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1582-4934.2008.00539.x     Document Type: Article

References (32)

1. Pulkkanen KJ, Yla-Herttuala S. Gene therapy for malignant glioma: current clinical status. Mol Ther. 2005, 12:585-98.
2. Donaldson SS, Laningham F, Fisher PG. Advances toward an understanding of brainstem gliomas. J Clin Oncol. 2006, 24:1266-72.
3. Hood JD, Cheresh DA. Role of integrins in cell invasion and migration. Nat Rev Cancer. 2002, 2:91-100.
4. Zagzag D, Friedlander DR, Margolis B. Molecular events implicated in brain tumor angiogenesis and invasion. Pediatr Neurosurg. 2000, 33:49-55.
5. Kitada S, Pedersen IM, Schimmer AD. Dysregulation of apoptosis genes in hematopoietic malignancies. Oncogene. 2002, 21:3459-74.
6. George J, Banik NL, Ray SK. Bcl-2 siRNA augments taxol mediated apoptotic death in human glioblastoma U138MG and U251MG cells. Neurochem Res. 2009, 34:66-78.
7. Nuydens R, Dispersyn G, Van Den Kieboom G. Bcl-2 protects neuronal cells against taxol-induced apoptosis by inducing multi-nucleation. Apoptosis. 2000, 5:335-43.
8. Ling X, Bernacki RJ, Brattain MG. Induction of survivin expression by taxol (paclitaxel) is an early event, which is independent of taxol-mediated G2/M arrest. J Biol Chem. 2004, 279:15196-203.
9. Ganesh T, Yang C, Norris A. Evaluation of the tubulin-bound paclitaxel conformation: synthesis, biology, and SAR studies of C-4 to C-3′ bridged paclitaxel analogues. J Med Chem. 2007, 50:713-25.
10. Huisman C, Ferreira CG, Broker LE. Paclitaxel triggers cell death primarily via caspase-independent routes in the non-small cell lung cancer cell line NCI-H460. Clin Cancer Res. 2002, 8:596-606.
11. George J, Tsutsumi M. siRNA-mediated knockdown of connective tissue growth factor prevents N-nitrosodimethylamine-induced hepatic fibrosis in rats. Gene Ther. 2007, 14:790-803.
12. Metrailler-Ruchonnet I, Pagano A, Carnesecchi S. Bcl-2 protects against hyperoxia-induced apoptosis through inhibition of the mitochondria-dependent pathway. Free Radic Biol Med. 2007, 42:1062-74.
13. Murphy KM, Ranganathan V, Farnsworth ML. Bcl-2 inhibits Bax translocation from cytosol to mitochondria during drug-induced apoptosis of human tumor cells. Cell Death Differ. 2000, 7:102-111.
14. Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods. 1983, 65:55-63.
15. Tolboom TC, Huizinga TW. In vitro matrigel fibroblast invasion assay. Methods Mol Med. 2007, 135:413-22.
16. Sckell A, Leunig M. Dorsal skinfold chamber preparation in mice - studying angiogenesis by intravital microscopy. Methods in molecular medicine - angiogenesis protocols 2001, Vol. 46:95-105. Murray JC, In, editor, Totowa, New Jersey, Humana Press, pp.
17. Wachsberger PR, Burd R, Marero N. Effect of the tumor vascular-damaging agent, ZD6126, on the radioresponse of U87 glioblastoma. Clin Cancer Res. 2005, 11:835-42.
18. Díaz JF, Strobe R, Engelborghs Y. Molecular recognition of taxol by microtubules. Kinetics and thermodynamics of binding of fluorescent taxol derivatives to an exposed site. J Biol Chem. 2000, 275:26265-76.
19. Ganesh T, Guza RC, Bane S. The bioactive Taxol conformation on β-tubulin: experimental evidence from highly active constrained analogs. Proc Natl Acad Sci USA. 2004, 101:10006-11.
20. George J, Gondi CS, Dinh DH. Restoration of tissue factor pathway inhibitor-2 in a human glioblastoma cell line triggers caspase-mediated pathway and apoptosis. Clin Cancer Res. 2007, 13:3507-17.
21. Karmakar S, Banik NL, Ray SK. Combination of all-trans retinoic acid and paclitaxel-induced differentiation and apoptosis in human glioblastoma U87MG xenografts in nude mice. Cancer. 2008, 112:596-607.
22. Wacheck V, Losert D, Günsberg P. Small interfering RNA targeting bcl-2 sensitizes malignant melanoma. Oligonucleotides. 2003, 13:393-400.
23. Lima RT, Martins LM, Guimarães JE. Specific downregulation of bcl-2 and XIAP by RNAi enhances the effects of chemotherapeutic agents in MCF-7 human breast cancer cells. Cancer Gene Ther. 2004, 11:309-16.
24. Westerlund A, Hujanen E, Höyhtyä M. Ovarian cancer cell invasion is inhibited by paclitaxel. Clin Exp Metastasis. 1997, 15:318-28.
25. Pandya NM, Dhalla NS, Santani DD. Angiogenesis - a new target for future therapy. Vascul Pharmacol. 2006, 44:265-74.
26. Machein MR, Plate KH. VEGF in brain tumors. J Neurooncol. 2000, 50:109-20.
27. Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors. Nat Med. 2003, 9:669-76.
28. Goh PP, Sze DM, Roufogalis BD. Molecular and cellular regulators of cancer angiogenesis. Curr Cancer Drug Targets. 2007, 7:743-58.
29. Hata K, Osaki M, Dhar DK. Evaluation of the antiangiogenic effect of taxol in a human epithelial ovarian carcinoma cell line. Cancer Chemother Pharmacol. 2004, 53:68-74.
30. Lei XY, Zhong M, Feng LF. siRNA-mediated Bcl-2 and Bcl-xL gene silencing sensitizes human hepatoblastoma cells to chemotherapeutic drugs. Clin Exp Pharmacol Physiol. 2007, 34:450-6.
31. Gondi CS, Lakka SS, Dinh DH. Intraperitoneal injection of a hairpin RNA-expressing plasmid targeting urokinase-type plasminogen activator (uPA) receptor and uPA retards angiogenesis and inhibits intracranial tumor growth in nude mice. Clin Cancer Res. 2007, 13:4051-60.
32. Larson SD, Jackson LN, Chen LA. Effectiveness of siRNA uptake in target tissues by various delivery methods. Surgery. 2007, 142:262-9.